Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of AZD1152 in Japanese Patients With Acute Myeloid Leukemia
jRCT2080220498Phase 1
- Sponsor
- AstraZeneca
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of barasertib in acute myeloid leukemia (AML), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of AZD1152 and Pharmacokinetics of AZD1152.
02
Drugs
barasertib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2080220498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220498.